Thus, pharmacological inhibition of LRH-1 may represent an interesting therapeutic option in the treatment of T-cell-dependent and FasL-mediated immunopathologies, such as hepatitis and acute Graft-versus-Host disease. This evidence concerns the gene FASLG and acute graft versus host disease.